Research Article Details
| Article ID: | A20714 |
| PMID: | 25785003 |
| Source: | Int J Clin Exp Med |
| Title: | Association between nonalcoholic fatty liver disease and colorectal adenoma: a systematic review and meta-analysis. |
| Abstract: | BACKGROUND AND AIMS: Several existing studies indicated that nonalcoholic fatty liver disease (NAFLD) may be associated with colorectal adenoma, but the results and risk factors are controversial. A systematic review of studies was conducted to explore these issues by meta-analysis. METHODS: We searched the Pubmed, Embase, Cochrane library, Medline and Web of Science databases for studies published before May 30(th), 2014. A statistical analysis was performed using RevMan 5.2 software. RESULTS: Seven studies involving 11,905 participants from different regions were included. Among them, five trials carried out subgroup of NAFLD patients in colorectal adenoma population. The result showed NAFLD was significantly correlated with adenoma of colon (Odds ratio [OR] = 1.56, 95% confidence interval [CI]: 1.22-1.99, P = 0.0003). It could be found in stratified analysis that patients had more chance to get multiple adenomas when they suffered NAFLD (Rate ratio [RR]: 1.52, 95% CI: 1.08-2.13, P = 0.02). Such risk factors of NAFLD as age, waist circumference, body mass index (BMI), disorder of lipid metabolism, hyperglycemia and high blood pressure (HBP) increased risk of colorectal adenoma (Age: mean difference [MD]: 2.81, 95% CI: 0.33-5.28; Waist: MD: 2.84, 95% CI: 2.14-3.54; BMI: MD: 0.85, 95% CI: 0.69-1.01; High-density lipoprotein: MD: -2.46, 95% CI: -3.68 to -1.24; Triglyceride: MD: 16.12, 95% CI: 8.89-23.36; Low-density lipoprotein: MD: 6.04, 95% CI: 3.60-8.48; Cholesterol: MD: 4.25, 95% CI: 0.87-7.63; Fasting glucose: MD: 2.27, 95% CI: 1.24-3.30; HBP: OR = 1.51, 95% CI: 1.22-1.88), while diabetes had no significant association with it (OR = 1.43, 95% CI: 0.94-2.17, P = 0.09). Besides, NAFLD didn't affect the location, size and advanced type of colorectal adenoma (P > 0.05). CONCLUSION: The present systematic review and meta-analysis demonstrated NAFLD was closely associated with great risk of colorectal adenoma and its number, but not with its location, size and advanced type. Waist, obesity, lipid profiles, glucose, hypertension played roles in the process of colorectal adenoma. |
| DOI: |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S02 | Enhance lipid metabolism | triglyceride-lowering; lipid tolerance; lipid metabolism | 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitor; Decreases intestinal cholesterol absorption; FXR agonist; ACC inhibitor; FAS inhibitor; DGAT2 inhibitor; SCD-1 inhibitor | Atorvastatin; Ezetimibe; Obeticholic Acid; GS-9674; GS-0976; TVB-2640; IONIS-DGAT2rx; Aramchol; | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I12 | 10763 | Hypertension | An artery disease characterized by chronic elevated blood pressure in the arteries. https://en.wikipedia.org/wiki/Hypertension, https://www.ncbi.nlm.nih.gov/pubmed/24352797 | disease of anatomical entity/ cardiovascular system disease/vascular disease/ artery disease | Details |
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D248 | Obeticholic Acid | Chemical drug | DB05990 | NR1H4 activator; NR1H4 agonist; FXR agonist | Enhance lipid metabolism | Approval rejected | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |